Disease · MONDO_0005154
Comparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 16 of 16
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Omegaven vs Intralipid: deaths from any cause | 3 of 42 | 12 of 49 | 91 | NCT00910104 | Trial comparisons |
| Omegaven vs Intralipid: serious adverse events | 0 of 42 | 0 of 49 | 91 | NCT00910104 | Trial comparisons |
| Maralixibat: ALGS vs Maralixibat: PFIC: deaths from any cause | 1 of 40 | 0 of 12 | 52 | NCT04168385 | Trial comparisons |
| Maralixibat: ALGS vs Maralixibat: PFIC: serious adverse events | 10 of 40 | 3 of 12 | 52 | NCT04168385 | Trial comparisons |
| Drug-Carbamazepine (Tegretol XR) vs Drug-Carbamazepine (Tegretol XR) Placebo: deaths from any cause | 0 of 13 | 2 of 7 | 20 | NCT01379469 | Trial comparisons |
| Drug-Carbamazepine (Tegretol XR) vs Drug-Carbamazepine (Tegretol XR) Placebo: serious adverse events | 6 of 13 | 4 of 7 | 20 | NCT01379469 | Trial comparisons |
| Sildenafil vs Placebo: deaths from any cause | 0 of 10 | 0 of 10 | 20 | NCT03154476 | Trial comparisons |
| Sildenafil vs Placebo: serious adverse events | 0 of 10 | 0 of 10 | 20 | NCT03154476 | Trial comparisons |
| VTS-270 at 500 mg/kg vs VTS-270 at 1000 mg/kg: Participants With Reduction in Liver Stiffness (kPa) | 0 of 1 | 0 of 1 | 2 | NCT03887533 | Trial comparisons |
| VTS-270 at 500 mg/kg vs VTS-270 at 1000 mg/kg: Participants With Reduction in Plasma Bile Acid B (5α) | 1 of 1 | 0 of 1 | 2 | NCT03887533 | Trial comparisons |
| VTS-270 at 500 mg/kg vs VTS-270 at 1000 mg/kg: Participants With Reduction in Aspartate Aminotransferase | 1 of 1 | 1 of 1 | 2 | NCT03887533 | Trial comparisons |
| VTS-270 at 500 mg/kg vs VTS-270 at 1000 mg/kg: Participants With Reduction in Plasma Cholestane-3β | 1 of 1 | 0 of 1 | 2 | NCT03887533 | Trial comparisons |
| VTS-270 at 500 mg/kg vs VTS-270 at 1000 mg/kg: Participants With Reduction in C-Triol (6β-triol) | 1 of 1 | 0 of 1 | 2 | NCT03887533 | Trial comparisons |
| VTS-270 at 500 mg/kg vs VTS-270 at 1000 mg/kg: Participants With Reduction in Alanine Aminotransferase Level | 0 of 1 | 0 of 1 | 2 | NCT03887533 | Trial comparisons |
| VTS-270 at 500 mg/kg vs VTS-270 at 1000 mg/kg: deaths from any cause | 0 of 1 | 0 of 1 | 2 | NCT03887533 | Trial comparisons |
| VTS-270 at 500 mg/kg vs VTS-270 at 1000 mg/kg: serious adverse events | 1 of 1 | 0 of 1 | 2 | NCT03887533 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005154/comparisons